HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

Edouard Januel 1 Jérôme de Seze 2 Patrick Vermersch 3 Elisabeth Maillart 4 Bertrand Bourre 5 Julie Pique 6 Xavier Moisset 7 Caroline Bensa 8 Adil Maarouf 9 Jean Pelletier 10 Sandra Vukusic 11 Bertrand Audoin 9 Céline Louapre 4, 1 Kevin Bigaut 12 Nathalie Derache 13 Salimata Gassama 14 Olivier Heinzlef 15 Laurent Kremer 16 Philippe Kerschen 17 Aude Maurousset Vito Ricigliano
1 ICM - Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute
2 Service de Neurologie [Strasbourg]
3 CHU Lille
4 Service de Neurologie [CHU Pitié-Salpêtrière]
5 Service de neurologie [Rouen]
6 MIRCEM - Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle
7 Neuro-Dol - Neuro-Dol
8 Service de Neurologie [CHU Nice]
9 CRMBM - Centre de résonance magnétique biologique et médicale
10 CHU Marseille
11 Département de Neuroradiologie [Centre Hospitalier Lyon Sud - HCL]
12 Centre d’Investigation Clinique Plurithématique (CIC - P) - CIC Strasbourg
13 Service de Neurologie [CHU Caen]
14 UNIROUEN UFR Santé - UNIROUEN - UFR Santé
15 CHI Poissy-Saint-Germain
16 LPHI - LPHI - Laboratory of Pathogen Host Interactions
17 ENT - Excitabilité nerveuse et thérapeutique
Abstract : Introduction: Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. Case series: We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild. Discussion: These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients, and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.
Document type :
Journal articles
Complete list of metadata
https://hal.sorbonne-universite.fr/hal-03526127
Contributor : Hal Sorbonne Université 5 Gestionnaire Connect in order to contact the contributor
Submitted on : Friday, January 14, 2022 - 11:53:55 AM
Last modification on : Friday, May 20, 2022 - 11:06:56 AM
Long-term archiving on: : Friday, April 15, 2022 - 6:39:11 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2022-07-14

Please log in to resquest access to the document

Identifiers

Collections

HCL | CRMBM | CHLS | ENT | UPEC-UPEM | UPEC | LPHI | ACL-SVSAE | ICM | UNIV-MONTPELLIER | UNIROUEN | UNIV-AMU | UNICAEN | SU-MEDECINE | SITE-ALSACE | COMUE-NORMANDIE | ND | CNRS | PRES_CLERMONT | SORBONNE-UNIVERSITE | SU-TI | INSERM

Citation

Edouard Januel, Jérôme de Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, et al.. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Multiple Sclerosis Journal, SAGE Publications, 2021, pp.135245852110497. ⟨10.1177/13524585211049737⟩. ⟨hal-03526127⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

65

 

contact